Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial

Although the treatment landscape for metastatic pancreatic cancer continues to evolve, it remains one of the deadliest malignancies worldwide (1). Gemcitabine in combination with nab-paclitaxel has long been considered a standard first-line regimen following the landmark MPACT trial, which demonstrated improved overall survival (OS) over gemcitabine monotherapy (2,3). However, the regimen is not without cost, namely, the substantial burden of toxicities, particularly peripheral neuropathy and hematologic adverse events, which often necessitate dose modifications.

Despite widespread clinical experience with gemcitabine-nab-paclitaxel, evidence-based approaches for dose reduction are lacking. The ALPACA trial by Dorman et al. (4) addresses this critical gap by evaluating a strategy of alternating treatment cycles with gemcitabine alone and standard combination therapy after an initial induction period of 3 months with gemcitabine-nab-paclitaxel. This multicenter, randomized, open-label, phase 2 study conducted across 29 centers in Germany assessed the feasibility of improving treatment tolerability without sacrificing efficacy.

A total of 325 patients with histologically confirmed metastatic pancreatic cancer were enrolled, 174 of whom were ultimately randomized following three cycles of standard induction chemotherapy. Patients were assigned to either continue the combination regimen or switch to an alternating schedule involving one monotherapy cycle followed by one combination therapy cycle. The primary endpoint was OS after randomization, and secondary outcomes included progression-free survival (PFS), response rate, and toxicity profile.

The results were compelling. Median OS was 10.4 months in the continuous treatment group and 10.5 months in the alternating group, with no statistically significant difference [hazard ratio (HR) =0.90; 80% confidence interval (CI): 0.72–1.13; P=0.56]. Similarly, PFS and response rates did not differ significantly between the two arms. However, the safety profile strongly favored the alternating schedule: rates of grade ≥3 peripheral neuropathy (14% vs. 21%), infections (11% vs. 20%), and other serious adverse events were consistently lower in the alternating arm.

The importance of these findings lies not only in statistical outcomes but also in clinical pragmatism. By alternating gemcitabine monotherapy with the full regimen, clinicians may reduce the cumulative toxicity while maintaining sufficient dose intensity. This is particularly salient in a patient population characterized by frailty, comorbidities, and limited functional reserve.

The context in which ALPACA was conducted should also be acknowledged. Previous exploratory analyses of the MPACT dataset suggested the potential benefits of dose modification (5), but these findings lacked prospective validation. ALPACA provided the first randomized evidence supporting a proactive, structured dose reduction strategy. This challenges the conventional notion that more intensive therapy always yields better outcomes, a particularly relevant consideration in diseases such as metastatic pancreatic cancer, where the quality of life is often as important as the length of life.

Moreover, the alternating regimen showed benefits in patient-reported outcomes such as the Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) scales, although the differences did not reach statistical significance in most cycles. These results suggest that the strategy reduces objective toxicity and may enhance subjective well-being, which is a meaningful endpoint in palliative oncology.

It is worth noting that ALPACA fits within the broader trend of personalized and adaptive treatment strategies. The concept of treatment de-intensification, which is well established in other malignancies, such as colorectal cancer, is now gaining traction in pancreatic cancer. Trials, such as PANOPTIMOX-PRODIGE 35 (6), have similarly explored maintenance and sequential treatment models. ALPACA extends this thinking to a gemcitabine-nab-paclitaxel backbone, which has long been considered inflexible because of its aggressive dosing.

Nevertheless, caution should be exercised in this regard. The ALPACA trial enrolled patients who achieved at least stable disease following induction therapy, potentially introducing a selection bias favoring tumors with more indolent biology. Furthermore, the open-label design of this trial may have influenced the reporting of subjective adverse events. Although encouraging, the findings should not be overgeneralized without confirmatory data. Moreover, additional methodological considerations must be addressed before adopting this alternating regimen as a new standard of care. Notably, the ALPACA trial design did not follow the conventional testing approach for superiority or non-inferiority. Instead, it aims to provide an unbiased estimation of the treatment effect using an 80% CI, rather than the traditional 95% CI. Although this exploratory approach reflects the practical philosophy of hypothesis generation, the number of observed events fell short of expectations, which was a key limitation. Additionally, the trial experienced a higher-than-anticipated dropout rate during the induction phase, which led to an underpowered sample size and precluded the planned statistical analysis of OS with the intended precision. Consequently, the trial lacked sufficient statistical power to detect significant differences between the treatment arms. Furthermore, there was an imbalance in baseline prognostic variables between groups, most notably in carbohydrate antigen 19-9 (CA19-9) concentrations, which were substantially higher in the standard treatment group {median 1,301.0 [interquartile range (IQR), 85.4–6,221.0] vs. 501.6 (IQR, 46.0–4,673.5) U/mL}. This discrepancy should be considered when interpreting the findings. Although a confirmatory phase 3 trial would be ideal to validate the alternative strategy and clarify its broader role in managing metastatic pancreatic cancer, such a trial may face significant challenges in terms of time, cost, and patient recruitment.

In conclusion, the ALPACA trial offers a clinically relevant alternative to continuous combination chemotherapy in patients with metastatic pancreatic cancer. These findings suggest that alternating cycles of gemcitabine and nab-paclitaxel with gemcitabine monotherapy preserves efficacy while improving tolerability, particularly in reducing severe peripheral neuropathy and infections. This strategy may represent a new paradigm of maintenance treatment for patients who achieve disease control after induction therapy, which considers both the biology of the disease and the patient’s lived experiences.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, HepatoBiliary Surgery and Nutrition. The article has undergone external peer review.

Peer Review File: Available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-315/prf

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-315/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48. [Crossref] [PubMed]
2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. [Crossref] [PubMed]
3. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107:dju413. [Crossref] [PubMed]
4. Dorman K, Boeck S, Caca K, et al. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2024;9:935-43. [Crossref] [PubMed]
5. Scheithauer W, Ramanathan RK, Moore M, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol 2016;7:469-78. [Crossref] [PubMed]
6. Dahan L, Williet N, Le Malicot K, et al. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. J Clin Oncol 2021;39:3242-50. [Crossref] [PubMed]